You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Novo Nordisk
since
auto-detected in 150 stories
3 hours ago
These are the stocks posting the largest moves premarket.
4 days ago
Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India ○
found
a story from CNBC ⚠️ › World News
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.
12 days ago
US approves new oral weight-loss pill developed by Eli Lilly ⊕
found
a story from The Guardian ⚠️ › International
Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy
The US Food and Drug Administration (FDA) gave the green light on Wednesday to a new oral we…
Eli Lilly wins US approval for weight-loss drug in pill form ⊕
found
a story from Financial Times ✅ › Financial Times
New drug Foundayo sets up battle with Novo Nordisk for oral obesity drugs
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market ⊕
The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.
22 days ago
India is launching cheap, weight-loss drugs and Novo Nordisk is betting on its brands to stay on top ⊖
Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.
25 days ago
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share ⊕
The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
35 days ago
TD Cowen downgrades Novo Nordisk on concerns over semaglutide patent loss, pipeline outlook ○
TD Cowen still sees shares of Novo Nordisk adding 6% from here.
36 days ago
Hims & Hers shares surge 50% after Novo Nordisk drops patent infringement case over compounded weight loss drugs ⊖
Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell Novo's branded medicines.
42 days ago
Why Novo Nordisk's Ireland expansion is key to fighting off Eli Lilly ○
found
Novo Nordisk is investing in a facility in Ireland as it expands its production capacities of the newly launched Wegovy pill, the Danish drugmaker said Monday.